SCHEMBL5651380

SCHEMBL5651380

Cc1ccc(S(=O)(=O)N2CCc3ccc(OC(=O)N(C)c4ccccc4)cc3C2)cc1

nearest known ligand 0.54

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
AKR1C3 P42330 7/20 0.54
OPRM1 P35372 2/20 0.49
OPRK1 P41145 2/20 0.49
ALDH1A1 P00352 2/20 0.48
HTT P42858 1/20 0.48
PKM P14618 1/20 0.47
MEN1 O00255 3/20 0.46
KMT2A Q03164 3/20 0.46
HRH3 Q9Y5N1 1/20 0.46
GAA P10253 1/20 0.46
CYP3A4 P08684 1/20 0.46
CYP2C19 P33261 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
NPSR1 Q6W5P4 1/20 0.46
AKR1C1 Q04828 1/20 0.46
ESR2 Q92731 1/20 0.46
MAPK1 P28482 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5652554 0.89 MEN1 (0.52) AKR1C3MEN1KMT2ACYP3A4CYP2C19
SCHEMBL5650744 0.85 HRH3 (0.62) AKR1C3ALDH1A1PKMHRH3ESR2
SCHEMBL5648307 0.81 KMT2A (0.52) AKR1C3ALDH1A1HTTMEN1KMT2A
SCHEMBL20389254 0.74 AKR1C3 (0.59) AKR1C3OPRM1OPRK1ALDH1A1MEN1
SCHEMBL13302259 0.74 KMT2A (0.77) AKR1C3ALDH1A1PKMMEN1KMT2A
SCHEMBL25270458 0.73 SMN1; SMN2 (0.71) ALDH1A1PKMMEN1KMT2ASMN1; SMN2
SCHEMBL17786050 0.71 AKR1C3 (0.73) AKR1C3OPRM1OPRK1AKR1C1ESR2
SCHEMBL14751054 0.71 AKR1C3 (0.65) AKR1C3ALDH1A1HTTPKMMEN1
SCHEMBL5647156 0.70 AKR1C3 (0.45) AKR1C3MEN1KMT2ASMN1; SMN2
SCHEMBL3281251 0.70 AKR1C3 (0.76) AKR1C3PKMAKR1C1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060148860-A1 Substituted p-phenyl carbamates NOVO NORDISK A/S (DK) 2006-07-06 US claimed
EP-1636188-A1 PARA-SUBSTITUTED PHENYL CARBAMATES AS INHIBITORS OF HORMONE SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2006-03-22 EP claimed
WO-2004111006-A1 PARA-SUBTITUTED PHENYL CARBAMATES AS INHIBITORS OF HORMONE SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2004-12-23 WO claimed
EP-1458374-A2 COMPOUNDS AND USES THEREOF FOR DECREASING ACTIVITY OF HORMONE-SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2004-09-22 EP claimed
US-20030166644-A1 Compounds and uses thereof for decreasing activity of hormone-sensitive lipase NOVO NORDISK A/S (DK) 2003-09-04 US claimed
WO-2003051841-A2 COMPOUNDS AND USES THEREOF FOR DECREASING ACTIVITY OF HORMONE-SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2003-06-26 WO claimed
US-7279470-B2 Compounds and uses thereof for decreasing activity of hormone-sensitive lipase NOVO NORDISK A/S (DK) 2007-10-09 US disclosed
US-20060148860-A1 Substituted p-phenyl carbamates NOVO NORDISK A/S (DK) 2006-07-06 US disclosed
US-7067517-B2 Use of compounds for decreasing activity of hormone-sensitive lipase NERO NORDISK A/S (DK) 2006-06-27 US disclosed
EP-1636188-A1 PARA-SUBSTITUTED PHENYL CARBAMATES AS INHIBITORS OF HORMONE SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2006-03-22 EP disclosed
WO-2004111006-A1 PARA-SUBTITUTED PHENYL CARBAMATES AS INHIBITORS OF HORMONE SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2004-12-23 WO disclosed
EP-1458374-A2 COMPOUNDS AND USES THEREOF FOR DECREASING ACTIVITY OF HORMONE-SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2004-09-22 EP disclosed
EP-1458375-A2 COMPOSITIONS FOR DECREASING ACTIVITY OF HORMONE-SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2004-09-22 EP disclosed
US-20030166644-A1 Compounds and uses thereof for decreasing activity of hormone-sensitive lipase NOVO NORDISK A/S (DK) 2003-09-04 US disclosed
US-20030166690-A1 Use of compounds for decreasing activity of hormone-sensitive NOVO NORDISK A/S (DK) 2003-09-04 US disclosed
WO-2003051841-A2 COMPOUNDS AND USES THEREOF FOR DECREASING ACTIVITY OF HORMONE-SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2003-06-26 WO disclosed
WO-2003051842-A2 COMPOSITIONS DECREASING ACTIVITY OF HORMONE-SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2003-06-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060148860-A1 Substituted p-phenyl carbamates LIPE, PNLIP, LPL AKR1C3 2215/4885OPRM1 3446/4885OPRK1 2494/4885
US-20030166644-A1 Compounds and uses thereof for decreasing activity of hormone-sensitive lipase LIPE, PNLIP, LPL AKR1C3 1902/4885OPRM1 4488/4885OPRK1 3775/4885
US-20030166690-A1 Use of compounds for decreasing activity of hormone-sensitive LIPE, PNLIP, LPL AKR1C3 2058/4885OPRM1 4020/4885OPRK1 2938/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.